Negative Allosteric mGlu5 Modulator Compounds for Glutamatergic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders related to glutamatergic neurotransmission, such as dementia, pain, anxiety, movement disorders, and schizophrenia, lack effective modulators of the metabotropic glutamate receptor mGlu5, which are implicated in these conditions.
Innovation Solution
Development of novel compounds that act as negative allosteric modulators of the mGlu5 receptor, including specific structures with substituents on a 5 or 6-membered monocyclic aromatic heterocyclic group, to regulate glutamatergic signaling and treat a wide range of diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological and psychiatric disorders are used, then existing therapeutic options are available, but effective modulators of the mGlu5 receptor are lacking
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of the compounds (substituents R1-R6, heterocyclic groups, linkers) to optimize mGlu5 receptor binding affinity and modulatory efficacy. This includes changing chemical structure parameters, molecular weight, lipophilicity, and functional group composition to achieve reliable therapeutic effects while maintaining adaptability to different neurological and psychiatric conditions
Solution Approach 2:
The patent achieves universality by developing mGlu5 modulator compounds that can treat multiple neurological and psychiatric disorders (dementia, pain, anxiety, movement disorders, schizophrenia) through a single mechanism of action. The compounds are designed to modulate glutamatergic neurotransmission across different brain regions and pathological conditions, providing versatile therapeutic applications
2Reliability
If novel compounds with specific heterocyclic substituents are developed, then mGlu5 receptor modulation is achieved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into distinct functional modules: a core heterocyclic structure (pyrimidine, pyridine, or triazole ring), variable substituent groups (R1-R6), and linker regions. This modular approach allows systematic optimization of each segment's contribution to binding efficacy while managing overall molecular complexity through structured design
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the heterocyclic rings (e.g., cyano groups at R3, halogen atoms at R4/R5, alkyl groups at R6) to enhance local interactions with the mGlu5 receptor binding site. Each substituent is strategically placed to provide specific molecular recognition features while maintaining overall structural manageability
Data Source
AI summary
The disclosures herein relate to novel compounds of formulawherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.